Oncolytics Biotech Inc. announced updates and progress regarding its REO 033 study and plans to hold a Type D meeting with the U.S. Food and Drug Administration to discuss registrational expansion and study design elements. Oncolytics Biotech Inc. is a biotechnology company focused on developing oncology immunotherapy treatments.
